British pharmaceutical major AstraZeneca announced on Tuesday a 27% rise in net profit for the second quarter of the year, buoyed by exceptional performance in the United States — its key growth market.
According to the company’s Q2 earnings statement, profit after tax reached $2.45 billion for the three months ending 30 June, a significant increase from the same period last year.
This surge follows AstraZeneca’s recent multi-billion-dollar investment in the US, which appears to be paying dividends through heightened market penetration and revenue gains.
| Metric | Q2 2024 | Year-on-Year Change |
| Net Profit (Post-Tax) | $2.45 billion | +27% |
| Key Market Contributor | United States | Record Growth |
| Investment Highlight | Multi-billion USD | Recently Announced |
The pharmaceutical firm, headquartered in Cambridge, has recently doubled down on its American footprint, aiming to secure a larger share in one of the world’s most competitive and lucrative healthcare markets.
The second-quarter figures reflect strong product performance, increased demand across therapeutic areas, and a robust sales trajectory in the US — now a central pillar of AstraZeneca’s global strategy. Further detailed financial disclosures and revenue breakdowns across divisions are expected in the company’s forthcoming full financial report.
